FL118 has been used to reduce migration and invasion in NSCLC and breast cancer derived CSCs by downregulating survivin expression and drug resistance inducing proteins, thus increasing the sensitivity to chemotherapeutic treatments [235, 236]. Here, BIRC5 is linked to non-small cell lung carcinoma.